MV-s-NAP
AXP000114.1 · Oncolytic virus
- Platform
- measles virus (Edmonston-NSe vaccine lineage)
- Originator
- Mayo Clinic
- Sponsor
- Mayo Clinic
Names
Virus
- Role
- Oncolytic
- Family
- Paramyxoviridae
- Virus
- measles morbillivirus (NCBI Taxonomy 11234)
- Strain
- Edmonston-NSe vaccine lineage
- Replication
- replicating
- Modifications
- secreted H. pylori neutrophil-activating protein cassette inserted
- Transgenes
- H. pylori NAP
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C173889
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04521764 | A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer | Recruiting | Phase 1 | 2020-09-23 | 2027-08-15 | 54 | Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic Breast Adenocarcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 36092362 | Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H . pylori immunostimulatory bacterial transgene. | Molecular therapy. Methods & clinical development | 2022 | cited by trial NCT04521764 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41542034 | Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy. | Molecular therapy. Oncology | 2026 | name in abstract: MV-s-NAP |
| PMID 41235176 | Oncolytic measles virotherapy encoding the neutrophil-activating protein is effective in synovial sarcoma. | Molecular therapy. Oncology | 2025 | name in abstract: MV-s-NAP |
| PMID 34196308 | Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. | The Journal of clinical investigation | 2021 | name in abstract: MV-s-NAP |
| PMID 22334023 | Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. | Molecular therapy : the journal of the American Society of Gene Therapy | 2012 | name in abstract: MV-s-NAP |
| PMID 21182995 | Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. | Vaccine | 2011 | name in abstract: MV-s-NAP |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA258239 | Novel multipronged Immunovirotherapy Approach for GBM Treatment | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2021–2025 | name in abstract: MV-s-NAP |
| P50CA116201 | Project 3: Measles virus based immunovirotherapy in the treatment of metastatic breast cancer | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2016–2021 | name in abstract: MV-s-NAP |
Notes
Edmonston-lineage measles virus encoding secreted Helicobacter pylori neutrophil-activating protein (NAP). Transgene is bacterial, so not an HGNC symbol.
How to cite
MV-s-NAP (AXP000114.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000114.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.